



RECEIVE

JUN 29 2001

TECH CENTER 1600/

AMENDMENT TRANSMITTAL LETTER			DOCKET NUMBER: P-LJ 3597	
SERIAL NO: 09/375,246	FILING DATE: August 16, 1999	EXAMINER: J. Souaya	GROUP ART UNIT: 1655	
INVENTION: METHODS FOR IDENTIFYING SOMATIC CHANGES IN GENOMIC SEQUENCES USEFUL FOR CANCER DIAGNOSIS AND PROGNOSIS				

TO COMMISSIONER FOR PATENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on June 20, 2001.

By: David A. Gay  
David A. Gay, Reg. No. 39,200

June 20, 2001  
Date of Signature

Transmitted herewith is a Response to Office Action mailed December 20, 2000 with attached Appendix A, in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- ☒ Petition for Extension of Time is enclosed (in duplicate).
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

## CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	23-20	- 23	- 0	x	\$9	\$18	= \$0	\$
INDEPENDENT CLAIMS	5-3	- 5	- 0	x	\$40	\$80	= \$0	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM		<input type="checkbox"/> YES	<input checked="" type="checkbox"/> NO		\$135	\$270	= \$0	\$
					TOTAL ADDITIONAL FEE		\$0	\$

- \* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.
- \*\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.
- \*\*\* If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST



Inventors: CHANG and Malkhosyan  
Serial No.: 09/375,246  
Filed: August 16, 1999  
Page 2

RECEIVED

JUN 29 2001

TECH CENTER 1600/2900

- X A check in the amount of \$445.00 is enclosed, which covers the fee for a three-month extension of time.
- X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- X Any additional filing fees required under 37 C.F.R. 1.16.
- X Any patent application processing fees under 37 C.F.R. 1.17.
- X ~~The~~ Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

June 20, 2001  
Date

David A. Gay  
David A. Gay  
Registration No. 39,200  
CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
7<sup>th</sup> Floor  
San Diego, California 92122  
858-535-9001  
USPTO CUSTOMER NO. 23601



PATENT

Our Docket: P-LJ 3597

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Perucho and Malkhosyan

Serial No: 09/375,246

Filed: August 16, 1999

For: METHODS FOR IDENTIFYING  
SOMATIC CHANGES IN  
GENOMIC SEQUENCES USEFUL  
FOR CANCER DIAGNOSIS AND  
PROGNOSIS

Examiner: J. Souaya

Group Art Unit: 1655

I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service as first class mail in an  
envelope addressed to: Commissioner for  
Patents, Washington, D.C., 20231 on  
June 20, 2001.

By: David A. Gay  
David A. Gay, Reg. No. 39,200

June 20, 2001  
Date of Signature

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed  
December 20, 2000, entry of the following amendments and remarks  
is respectfully requested.

AMENDMENTS

Please amend the claims as follows:

3. (Amended) The method of claim 1, wherein said  
first clinical outcome is increased risk of the recurrence of  
said cancer.

4. (Amended) The method of claim 1, wherein said  
second clinical outcome is decreased risk of the recurrence of  
said cancer.